Our mission is to eliminate inaccuracy and waste when translating drug candidates to clinical trials using AI-driven, multi-disciplinary quantitative methods that predict patient outcomes.
Our service offerings deliver insights for pharmaceutical companies, biotechs, and academic & research institutions. We also partner in risk-sharing collaborations to develop promising drugs.
PulmoSIM Therapeutics, a wholly-owned subsidiary of VeriSIM Life, identifies licensable candidates for preclinical translation and out-licensing to commercialization partners.
Addressing the unmet needs of patients everywhere is our passion. Are you motivated by ownership in your work and a mission to make a difference? Do you embrace diversity? Is continuous learning part of your DNA? This is what drives the team at VeriSIM Life every day. Learn more about our mission and make up.
San Francisco, CA, May 9th, 2023 - VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced a webinar hosted by CEO and Founder Dr. Jo Varshney, PhD and Dr. Jeff Barrett, PhD, Chief Science Officer at Aridhia Digital Research Environment (https://www.aridhia.com).
VeriSIM Life (VeriSIM) www.verisimlife.com, the leading artificial intelligence (AI)-enabled, unique R&D decisions de-risker for breakthrough drug development, today announced a partnership with Clarivate www.clarivate.com, a global leader in connecting people and organizations to intelligence they can trust.
Frost & Sullivan recently assessed the artificial intelligence (AI)-enabled preclinical development industry, and, based on its analysis results, recognizes VeriSIM Life with the 2022 North America Competitive Strategy Leadership Award.